Grace Frank, senior copy editor —

While there are few silver linings to the cloud created by COVID-19, the pandemic that has killed tens of thousands, hobbled economies worldwide and drove millions to quarantine in their homes, one may be a new appreciation of telemedicine. “If something good could come out of this crisis, it’s that…

A majority of cystic fibrosis patients who took part in an Instagram poll by Bionews Services said they would be interested in moving from current treatments to Trikafta (elexacaftor, tezacaftor, and ivacaftor), the newly approved and “next-generation” combination therapy by Vertex that is expected to treat 90% of all…

Vertex Pharmaceuticals has taken a major step toward treating 90% of all people with cystic fibrosis (CF), its long-stated goal, with the U.S. Food and Drug Administration’s approval of Trikafta (elexacaftor, tezacaftor, and ivacaftor) as a next-generation, triple combination treatment for CF. This triple combination treats people with the most…

Screening newborns for genetic diseases with treatments that can prevent crippling or deadly progression, especially for rare disorders, has a ways to go in the United States. No state today tests for all 35 disorders recommended under a federal screening panel, and even in those that come close, rare…

News that you’ve just been rejected for a necessary double-lung transplant rarely brings out the best in people. But Caleigh Haber, 27, a self-described fighter since being diagnosed with cystic fibrosis at birth, simply “wasn’t ready to wave the white flag,” she said in an interview with Cystic Fibrosis News…